Trial Profile

Explore the Relationship Between Single Nucleotide Polymorphisms and Crizotinib Response and Toxicity in Patients With Non-Small Cell Lung Cancer

Status: Not yet recruiting

Phase of Trial: Phase II/III

Latest Information Update: 22 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Afatinib (Primary) ; Crizotinib (Primary)
Indications Non-small cell lung cancer
Focus Pharmacodynamics; Pharmacogenomic
Acronyms Drugs-SNPs

Most Recent Events

13 Dec 2023 The protocol has been amended to reduction in Drug arm Afatinib.
13 Dec 2023 Planned initiation date changed from 28 Oct 2023 to 28 Mar 2024.
05 Oct 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com